Current status and future directions in antiplatelet therapy

Drugs of the Future

Volumn 34, Issue 1, 2009, Pages 27-41

  Krakat, J ^a   Mousa, S ^a   Root, R ^a   Mousa, S S ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 NTX 99; 2NTX 99; 3A,4,4A,5,6,7,8,8A,9,9A DECAHYDRO N [4 [2 [5 (3 FLUOROPHENYL) 2 PYRIDYL]VINYL] 3 METHYL 1 OXO 3H BENZO[F]ISOBENZOFURAN 7 YL]CARBAMIC ACID ETHYL ESTER; ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CANGRELOR; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FR 171113; NQ 12; PENTOXIFYLLINE; PICOTAMIDE; PLACEBO; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; PURINERGIC P2Y12 RECEPTOR ANTAGONIST; RECEPTOR ANTIBODY; RECEPTOR BLOCKING AGENT; TERUTROBAN; THIENOPYRIDINE DERIVATIVE; THROMBIN INHIBITOR; THROMBIN RECEPTOR; TICAGRELOR; TICLOPIDINE; TIROFIBAN; TRIFLUSAL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTERY DISEASE; BLEEDING; BLEEDING TENDENCY; BONE MARROW APLASIA; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY STENT; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SYNTHESIS; DYSPNEA; HEART VALVE PROSTHESIS; HUMAN; HYPOTENSION; INTERMITTENT CLAUDICATION; LOADING DRUG DOSE; NAUSEA; NEUTROPENIA; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL VASCULAR DISEASE; RASH; REVIEW; RISK FACTOR; RISK REDUCTION; STENT THROMBOSIS; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; VOMITING;

EID: 76649105432     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2009.034.01.1315100     Document Type: Review

References (117)

1. Stevens, M.L. Fundamentals of Clinical Hematology. W.B. Saunders Company, Philadelphia, 1997.
2. Hambleton, J. Drugs Used in Disorders of Coagulation, in Basic & Clinical Pharmacology. B.G. Katzung (Ed.). McGraw-Hill, New York, 2004, 543-60.
3. Cattaneo, M. Aspirin and clopidogrel: Efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004, 24(11): 1980-7.
4. Sudlow, C. What is the role of dipyridamole in long-term secondary prevention after an ischemic stroke or transient ischemic attack? CMAJ 2005, 173(9): 1024-6.
5. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324(7329): 71-86.
6. Fugate, S.E., Cudd, L.A. Cangrelor for treatment of coronary thrombosis. Ann Pharmacother 2006, 40(5): 925-30.
7. Eikelboom, J.W., Hirsh, J., Weitz, J.I., Johnston, M., Yi, Q., Yusuf, S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002, 105(14): 1650-5.
8. Husted, S. New developments in oral antiplatelet therapy. Eur Heart J Suppl 2007,9(Suppl. D): D20-7.
9. Gaussem, P., Reny, J.L, Thalamos, C. et al. The specific thromboxane receptor antagonist S18886: Pharmacokinetic and pharmacodynamic studies. J Thromb Haemost 2005, 3(7): 1437-45.
10. Osende, J.I., Shimbo, D., Fuster, V., Dubar, M., Badimon, J.J. Antithrombotic effects of S 18886, a novel orally active thromboxane A2 receptor antagonist. J Thromb Haemost 2004, 2(3): 492-8.
11. Celestini, A., Violi, F. A review of picotamide in the reduction of cardiovascular events in diabetic patients. Vasc Health Risk Manag 2007, 3(1): 93-8.
12. Vezza, R., Spina, D., Tallarida, R.J., Nathan, M., Page, C.P., Gresele, P. Antivasoconstrictor and antiaggregatory activities of picotamide unrelated to thromboxane A2 antagonism. Thromb Haemost 1997, 78(5): 1385-91.
13. Balsano, F., Violi, F. Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. The ADEP Group. Circulation 1993, 87(5): 1563-9.
14. Milani, M., Longoni, A., Maderna, M. Effects of picotamide, an antiplatelet agent, on cardiovascular, events in 438 claudicant patients with diabetes: A retrospective analysis of the ADEP study. Br J Clin Pharmacol 1996, 42(6): 782-5.
15. Neri Serneri, G.G., Coccheri, S., Marubini, E. et al. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: The DAVID study. Eur Heart J 2004, 25(20): 1845-52.
16. Buccellati, C., Sala, A., Rossoni, G. et al. Pharmacological characterization of 2NTX-99 [4-methoxy-N1-(4-trans-nitrooxycyclohexyl)-N3-(3- pyridinyl-methyl)-1,3-benzenedicarboxomide], a potential antiatherothrombotic agent with antithromboxane and nitric oxide donor activity in platelet and vascular preparations. J Pharmacol Exp Ther 2006, 317(2): 830-7.
17. Nile Therapeutics, Inc. Pipeline, www.nilethera.com.
18. Jin, Y.R., Han, X.H., Lee, J.J. et al. Antiplatelet effect of NQ12: A possible mechanism through the arachidonic acid cascade. J Pharmacol Sci 2007, 105(2): 193-200.
19. Springthorpe, B., Bailey, A., Barton, P. et al. From ATP to AZD6140: The discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis. Bioorg Med Chem Lett 2007, 17(21): 6013-8.
20. Angiolillo, D.J. ADP receptor antagonism: What's in the pipeline? Am J Cardiovasc Drugs 2007, 7(6): 423-32.
21. Cattaneo, M. Platelet P2 receptors: Old and new targets for antithrombotic drugs. Expert Rev Cardiovasc Ther 2007, 5(1): 45-55.
22. Chattaraj, S.C. Cangrelor AstraZeneca. Curr Opin Investig Drugs 2001, 2(2): 250-5.
23. Kunapuli, S.P., Ding, Z., Dorsam, R.T., Kim, S., Murugappan, S., Quinton, T.M. ADP receptors -Targets for developing antithrombotic agents. Curr Pharm Des 2003, 9(28): 2303-16.
24. Storey, R.F. The P2Y12 receptor as a therapeutic target in cardiovascular disease. Platelets 2001, 12(4): 197-209.
25. Siller-Matula, J., Schrör, K., Wojta, J., Huber, K. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thromb Haemost 2007, 97(3): 385-93.
26. Savi, P., Pereillo, J.M., Uzabiaga, M.F. et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000, 84(5): 891-6.
27. Jakubowski, J.A., Payne, C.D., Weerakkody, G.J. et al. Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects. J Cardiovasc Pharmacol 2007, 49(3): 167-73.
28. Quinn, M.J., Fitzgerald, D.J. Ticlopidine and clopidogrel. Circulation 1999, 100(15): 1667-72.
29. Gent, M., Blakely, J.A., Easton, J.D. et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989, 1(8649): 1215-20.
30. Hass, W.K., Easton, J.D., Adams, H.P. Jr. et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989, 321(8): 501-7.
31. Balsano, F., Rizzon, P., Violi, F. et al. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio delta Ticlopidina nell'Angina Instabile Group. Circulation 1990, 82(1): 17-26.
32. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994, 308(6921): 81-106.
33. Balsano, F., Coccheri, S., Libretti, A. et al. Ticlopidine in the treatment of intermittent claudication: A 21-month double-blind trial. J Lab Clin Med 1989, 114(1): 84-91.
34. Bergqvist, D., Almgren, B., Dickinson, J.P. Reduction of requirement for leg vascular surgery during long-term treatment of claudicant patients with ticlopidine: Results from the Swedish Ticlopidine Multicentre Study (STIMS). Eur J Vasc Endovasc Surg 1995, 10(1): 69-76.
35. Becquemin, J.P. Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. Etude de la Ticlopidine apres Pontage Femoro-Poplite and the Association Universitaire de Recherche en Chirurgie. N Engl J Med 1997, 337(24): 1726-31.
36. Castelli, P., Basellini, A., Agus, G.B. et al. Thrombosis prevention with ticlopidine after femoropopliteal thromboendarterectomy. Int Surg 1986, 71(4): 252-5.
37. Boissel, J.P., Peyrieux, J.C., Destors, J.M. Is it possible to reduce the risk of cardiovascular events in subjects suffering from intermittent claudication of the lower limbs? Thromb Haemost 1989, 62(2): 681-5.
38. Janzon, L., Bergqvist, G., Boberg, J. et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med 1990, 227(5): 301-8.
39. Janzon, L. The STIMS trial: The ticlopidine experience and its clinical applications. Swedish Ticlopidine Multicenter Study. Vasc Med 1996, 1(2): 141-3.
40. Leon, M.B., Baim, D.S., Popma, J.J. et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998, 339(23): 1665-71.
41. Bertrand, M.E., Legrand, V., Boland, J. et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation 1998, 98(16): 1597-603.
42. Urban, P., et al., Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: The multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 1998, 98(20): 2126-32.
43. Savi, P., Herbert, J.M. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 2005, 31(2): 174-83.
44. McTavish, D., Faulds, D., Goa, K.L. Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders. Drugs 1990, 40(2): 238-59.
45. Gill, S., Majumdar, S., Brown, N.E., Armstrong, P.W. Ticlopidine- associated pancytopenia: Implications of an acetylsalicylic acid alternative. Can J Cardiol 1997, 13(10): 909-13.
46. Bennett, C.L.,Weinberg, P.D., Rozenberg-Ben-Dror, K., Yarnold, P.R., Kwaan, H.C., Green, D. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med 1998, 128(7): 541-4.
47. Kupfer, Y., Tessler, S. Ticlopidine and thrombotic thrombocytopenic purpura. N Engl J Med 1997, 337(17): 1245.
48. Page, Y., Tardy, B., Zeni, F., Comtet, C., Terrana, R., Bertrand, J.C. Thrombotic thrombocytopenic purpura related to ticlopidine. Lancet 1991, 337(8744): 774-6.
49. Patrono, C., Coller, B., FitzGerald, G.A., Hirsh, J., Roth, G. Platelet-active drugs: The relationships among dose, effectiveness, and side effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126(3, Suppl.): 234S-64S.
50. Denninger, M.H., Necciari, J., Serre-Lacroix, E., Sissmann, J. Clopidogrel antiplatelet activity is independent of age and presence of atherosclerosis. Semin Thromb Hemost 1999, 25(Suppl. 2): 41-5.
51. Fares, R.R., Lansing, L.S., Gallati, C.A., Mousa, S.A. Antiplatelet therapy with clopidogrel and aspirin in vascular diseases: Clinical evidence for and against the combination. Expert Opin Pharmacother 2008, 9(3): 377-86.
52. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348(9038): 1329-39.
53. Bhatt, D.L., Hirsch, A.T., Ringleb, P.A., Hacke, W., Topol, E.J. Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. Am Heart J 2000, 140(1): 67-73.
54. Ringleb, P.A., Bhatt, D.L., Hirsch, A.T. et al. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke 2004, 35(2): 528-32.
55. Mehta, S.R., Yusuf, S., Peters, R.J. et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001, 358(9281): 527-33.
56. Cannon, C.P., Husted, S., Harrington, R.A. et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: Primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007, 50(19): 1844-51.
57. Braunwald, E., Antman, E.M., Beasley, J.W. et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - summary article: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002, 40(7): 1366-74.
58. Kapetanakis, E.I., Medlam, D.A., Petro, K.R. et al. Effect of clopidogrel premedication in off-pump cardiac surgery: Are we forfeiting the benefits of reduced hemorrhagic sequelae? Circulation 2006, 113(13): 1667-74.
59. Fares, R.R., Lansing, L.S., Gallati, C.A., Mousa, S.A. Antiplatelet therapy with clopidogrel and aspirin in vascular diseases: Clinical evidence for and against the combination. Expert Opin Pharmacother 2008, 9(3): 377-86.
60. Tantry, U.S., Bliden, K.P., Gurbel, P.A. Azd6140. Expert Opin Investig Drugs 2007, 16(2): 225-9.
61. Gurbel, P.A., Bliden, K.P., Hiatt, B.L., O'Connor, C.M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003, 107(23): 2908-13.
62. Gurbel, P.A., Bliden, K.P., Hayes, K.M., Yoho, J.A., Herzog, W.R., Tantry, U.S. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005, 45(9): 1392-6.
63. Angiolillo, D.J., Fernandez-Ortiz, A., Bernardo, E., Alfonso, F., Macaya, C., Bass, T.A., Costa, M.A. Variability in individual responsiveness to clopidogrel: Clinical implications, management, and future perspectives. J Am Coll Cardiol 2007, 49(14): 1505-16.
64. Angiolillo, D.J., Shoemaker, S.B., Desai, B. et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 2007, 115(6): 708-16.
65. Storey, R.F., Husted, S., Harrington, R.A. et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007, 50(19): 1852-6.
66. Mutier, I. et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001, 85(1): 92-3.
67. Wiviott, S.D., Trenk, D., Frelinger, A.L. et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007,116(25): 2923-32.
68. Niitsu, Y., Jakubowski, J.A., Sugidachi, A., Asai, F. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost 2005, 31(2): 184-94.
69. Farid, N.A., Payne, C.D., Small, D.S. et al. Cytochrome P450 3A inhibition by ketoconozole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007, 81(5): 735-41.
70. Jernberg, T., Payne, C.D., Winters, K.J. et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006, 27(10): 1166-73.
71. Wiviott, S.D., Braunwald, E., McCabe, C.H. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007, 357(20): 2001-15.
72. van Giezen, J.J., Humphries, R.G. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost 2005, 31(2): 195-204.
73. Greenbaum, A.B., Grines, C.L., Bittl, J.A. et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: Results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J 2006, 151(3): 689 e1-689 e10.
74. Storey, R.F., Oldroyd, K.G., Wilcox, R.G. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost 2001, 85(3): 401-7.
75. Steinhubl, S.R., Oh, J.J., Oestreich, J.H., Ferraris, S., Charnigo, R., Akers, W.S. Transitioning patients from cangrelor to clopidogrel: Pharmacodynamic evidence of a competitive effect. Thromb Res 2008, 121(4): 527-34.
76. Husted, S., Emanuelsson, H., Heptinstall, S., Sandset, P.M.,Wickens, M., Peters, G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: A double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006, 27(9): 1038-47.
77. Jones, L., Griffin, S., Palme, S. et al. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: A systematic review and economic evaluation. Health Technol Assess 2004, 8(38): iii-iv, 1-196.
78. Diener, H.C., Cunha, L., Forbes, C., Sivenius, J., Smet, P., Lowenthal, A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996, 143(1-2): 1-13.
79. Bennett, J.S., Mousa, S. Platelet function inhibitors in the year 2000. Thromb Haemost 2001, 85(3): 395-400.
80. Min, P.K., Jung, J.H., Ko, Y.G., Choi, D., Jang, Y., Shim, W.H. Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting: A quantitative coronary angiography and volumetric intravascular ultrasound study. Circ J 2007, 71(11): 1685-90.
81. Money, S.R., Herd, J.A., Isaacsohn, J.L., Davidson, M., Cutler, B., Heckman, J., Forbes, W.P. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 1998, 27(2): 267-74; discussion 274-5.
82. Beebe, H.G., Dawson, D.L., Cutler, B.S., Herd, J.A., Strandness, D.E. Jr., Bortey, E.B., Forbes, W.P. A new pharmacological treatment for intermittent claudication: Results of a randomized, multicenter trial. Arch Intern Med 1999, 159(17): 2041-50.
83. Park, S.W., Lee, C.W., Kim, H.S. et al. Comparison of cilostazol versus ticlopidine therapy after stent implantation. Am J Cardiol 1999, 84(5): 511-4.
84. Tsuchikane, E., Fukuhara, A., Kobayashi, T. et al. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation 1999, 100(1): 21-6.
85. Yoon, Y., Shim, W.H., Lee, D.H., Pyun, W.B., Kim, I.J., Jang, Y., Cho, S.Y. Usefulness of cilostazol versus ticlopidine in coronary artery stenting. Am J Cardiol 1999, 84(12): 1375-80.
86. Wang, X., Dorsam, R.T., Lauver, A. et al. Comparative analysis of various platelet glycoprotein llb/llla antagonists on shear-induced platelet activation and adhesion. J Pharmacol Exp Ther 2002, 303(3): 1114-20.
87. Clappers, N., Brouwer, M.A., Verheugt, F.W. Antiplatelet treatment for coronary heart disease. Heart 2007, 93(2): 258-65.
88. Freson, K., Thys, C., Wittevrongel, C., Van Geet, C. Mechanisms of action and targets for actual and future antiplatelet drugs. Mini Rev Med Chem 2006, 6(6): 719-26.
89. Antoniucci, D. Differences among GP llb/llla inhibitors: Different clinical ben7 efits in non-ST-segment elevation acute coronary syndrome percutaneous coronary intervention patients. Eur Heart J Suppl 2007, 9(Suppl. A): A32-6.
90. Tepe, G., Wiskirchen, J., Pereira, P., Claussen, C.D., Miller, S., Duda, S.H. GP llb/llla blockade during peripheral artery interventions. Cardiovasc Intervent Radiol 2008, 31(1): 8-13.
91. Topol, E.J., Moliterno, D.J., Herrmann, H.C. et al. Comparison of two platelet glycoprotein llb/llla inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001, 344(25): 1888-94.
92. Tricoci, P., Peterson, D.E., Chen, A. et al. Timing of glycoprotein llb/llla inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE). Am J Cardiol 2007, 99(10): 1389-93.
93. Montalescot, G., Borentain, M., Payot, L., Collet, J.P., Thomas, D. Early vs late administration of glycoprotein llb/llla inhibitors in primary percuta-neous coronary intervention of acute ST-segment elevation myocardial infarction: A meta-analysis. JAMA 2004, 292(3): 362-6.
94. Stone, G.W., Bertrand, M.E, Moses, J.W. et al. Routine upstream initiation vs deferred selective use of glycoprotein llb/llla inhibitors in acute coronary syndromes: The ACUITY Timing trial. JAMA 2007, 297(6): 591-602.
95. Hernandez, A.V. et al. Effects of platelet glycoprotein llb/llla receptor blockers in non-ST segment elevation acute coronary syndromes: Benefit and harm in different age subgroups. Heart 2007, 93(4): 450-5.
96. Cohen, M., Diez, J.E., Levine, G.N. et al. Pharmacoinvaslve management of acute coronary syndrome: Incorporating the 2007 ACC/AHA guidelines: the CATH (cardiac catheterization and antithrombotic therapy in the hospital) Clinical Consensus Panel Report-III. J Invasive Cardiol 2007, 19(12): 525-38; quiz 539-40.
97. Aster, R.H. Immune thrombocytopenia caused by glycoprotein llb/llla inhibitors. Chest 2005, 127(2, Suppl.): 53S-59S.
98. Seiffert, D., Stern, A.M., Ebling, W. et al. Prospective testing for drug-dependent antibodies reduces the incidence of thrombocytopenia observed with the small molecule glycoprotein llb/llla antagonist roxifiban: Implications for the etiology of thrombocytopenia. Blood 2003, 101(1): 58-63.
99. Mousa, S.A., Giugliano, R. Antiplatelet therapies: Platelet GPllb/llla antagonists and beyond. In: New Therapeutic Agents in Thrombosis. Sasahara, A.A. (Ed.). Marcel Dekker, New York, 2003, 341-7.
100. Lehman, S.J., Chew, D.P. Bivalirudin in percutaneous coronary intervention. Vasc Health Risk Manag 2006, 2(4): 357-63.
101. Bauer, K.A. New anticoagulants. Hematology Am Soc Hematol Educ Program 2006, 450-6.
102. Speredelozzi, N., Baroletti, S., Fanikos, J. A review of antithrombotic therapies in acute coronary syndrome. Formulary 2007, 42(3): 150-62.
103. Flaker, G.C., Gruber, M., Connolly, S.J. et al. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: An exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Am Heart J 2006, 152(5): 967-73.
104. Kaul, S., Diamond, G.A., Weintraub, W.S. Trials and tribulations of non-inferiority: The ximelagatran experience. J Am Coll Cardiol 2005, 46(11): 1986-95.
105. Eriksson, B.I., Dahl, O.E., Rosencher, N. et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomised, double-blind, non-inferiority trial. Lancet 2007, 370(9591): 949-56.
106. Ezekowitz, M.D., Reilly, P.A., Nehmiz, G. et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007, 100(9): 1419-26.
107. Chackalamannil, S., Wang, Y., Greenlee, W.J. et al. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem 2008, 51(11): 3061-4.
108. Kato, Y., Kita, Y., Hirasawa-Taniyama, Y. et al. Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig. Eur J Pharmacol 2003, 473(2-3): 163-9.
109. Greenbaum, A.B., Ohman, E.M., Gibson, C.M. et al. Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: Results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial. Am Heart J 2007, 154(4): 702-9.
110. Emmons, K.L., Taylor, N.R. Contemporary issues in clopidogrel therapy: New evidence shaping clinical practice. Pharmacotherapy 2007, 27(4): 553-63.
111. Fitzgerald, D.J. et al. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 1988, 77(1): 142-50.
112. Lange, R.A., Hillis, L.D. Concurrent antiplatelet and fibrinolytic therapy. N Engl J Med 2005, 352(12): 1248-50.
113. Sinnaeve, P.R., Huang, Y., Bogaerts, K. et al. Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: Findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS. Am Heart J 2006, 152(4): 684 e1-9.
114. Fanikos, J., Seybert, A., Spinier, S. Anticoagulation in non-ST-segment elevation acute coronary syndromes (NSTE ACS): Emerging therapeutic options. 2007, NSTAR.
115. Stone, G.W., Ware, J.H., Bertrand, M.E. et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: One-year results from the ACUITY trial. JAMA 2007, 298(21): 2497-506.
116. van Es, R.F., Jonker, J.J., Verheugt, F.W. et al. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): A randomised controlled trial. Lancet 2002, 360(9327): 109-13.
117. Hurlen, M., Abdelnoor, M., Smith, P., Erikssen, J., Arnesen, H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002, 347(13): 969-74.